Denali Therapeutics Inc. DNLI Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s investing cash flow?
- Denali Therapeutics Inc. (DNLI) reported investing cash flow of $94.46M in Q1 2026.
- How has Denali Therapeutics Inc.'s investing cash flow changed year-over-year?
- Denali Therapeutics Inc.'s investing cash flow increased by 403.8% year-over-year, from $18.75M to $94.46M.
- What is the long-term trend for Denali Therapeutics Inc.'s investing cash flow?
- Over 2 years (2021 to 2025), Denali Therapeutics Inc.'s investing cash flow has grown at a 243.6% compound annual growth rate (CAGR), from -$21.63M to $255.28M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.